Live Breaking News & Updates on பயோடெக் மற்றும் பார்மா

Stay informed with the latest breaking news from பயோடெக் மற்றும் பார்மா on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in பயோடெக் மற்றும் பார்மா and stay connected to the pulse of your community

Netflix Reports Earnings Today. Can It Restart the Tech Rally?

Text size
Earnings season started last week with results from
JPMorgan
and other big banks. Or did it? For many investors, it doesn’t really begin until
Netflix,
the first of the big tech stocks, reports after Tuesday’s close.
Tech looms over the market. The FAANG stocks plus
Microsoft
have a combined market cap of more than $7 trillion, or roughly 22% of the total value of the
And big tech has been stuck. The FAANG+M stocks have risen an average of just 1.4% over the past three months, trailing the 8% gain of the market. Banks and energy stocks have risen more than 40% over that period.

Netflix , Microsoft , Getty-images , Biotechnology , Printing-publishing , Trusts-funds-financial-vehicles , Private-equity , Healthcare-life-sciences , Alternative-investments , Media-content-distribution , Financial-services

News Updates: Trump Expected to Issue Many Pardons on Final Day in Office

Order Reprints
Print Article
Text size
•
Senate Majority Leader Mitch McConnell criticized President Donald Trump’s role in fomenting the mob that stormed the Capitol building on Jan 6. “The mob was fed lies,” McConnell said on the Senate floor. “They were provoked by the president and other powerful people.” The Senate will soon begin outgoing President Trump’s second impeachment trial and McConnell, who will become the minority leader once Democrats take control of the chamber, has not yet publicly said how he will vote, but has increased his criticism of Trump after years of being wary of doing so.

New-york , United-states , Washington , Americans , Donald-trump , Ben-walsh , Rudy-giuliani , Andrew-cuomo , Pfizer , West-wing , White-house , Getty-images

W.R. Grace, GameStop See Activist Action

W.R. Grace (GRA)
40 North Management revealed a 14.9% interest in W.R. Grace, equal to 9,865,008 shares of the maker of specialty chemicals. On Nov. 9, 40 North offered to take W.R. Grace private for $60.00 cash per share. That offer was rejected by W.R. Grace’s board, and prompted 40 North to raise its bid to $65.00 per...
Close
From

Ryan-cohen , Exchange-commission , Rocket-pharmaceuticals , Genco-shipping , Gamestop , David-partner , Value-partners , Strategic-value , Chemicals , Basic-materials-resources , Industrial-goods , Packaging

The Stock Market Fell the Most Since October. Why Big Tech Is Part of the Problem.

Order Reprints
Text size
Medical workers carry cold storage boxes containing injection material during a Phase 3 trial of the Johnson & Johnson Covid-19 vaccine.
Angel Garcia/Bloomberg
The stock market hasn’t been this spooked since Halloween.
The
Dow Jones Industrial Average
slipped 283.71 points, or 0.9%, this past week, to 30,814.26, while the
Nasdaq Composite
dropped 1.5%, to 12,998.50. The S&P 500 fell 1.5%, to 3768.25, its largest decline since the week ended Oct. 30, though back then it dropped 5.6%. Still, it was the
S&P 500’s
first weekly drop of more than 1% since then, a sign that investors, unflappable until now, really were taken aback by what they saw.

Angel-garcia-bloomberg , Johnson-covid , Nasdaq , Dow-jones-industrial-average , Nasdaq-composite , Pharmaceuticals , Vaccines , Textiles , Wholesalers , Retail-wholesale , Healthcare-life-sciences , Clothing-textiles

Stocks Could Have a Muted Year, Even if the Economy Booms

Order Reprints
Illustrations by Helen Green
Welcome to the Roaring ’20s. When the world finally bids good riddance to Covid-19, courtesy of a bevy of novel vaccines, expect Americans to emerge from their lairs with a joie de vivre not seen since the 1920s. That’s marvelous news for the economy, which could use some cheer after a punishing year, and for the many companies that will help keep the good times rolling.
Just don’t expect the party on Main Street to spread to Wall Street, which had a rollicking celebration of its own this past year. As a consequence, stock...

United-states , Americans , Main-street , Wall-street , Pharmaceuticals , Healthcare-life-sciences , Financial-performance , Earnings , Corporate-industrial-news , Political-general-news , Respiratory-tract-diseases

New Data Boosts Confidence In J&J Vaccine

New data on early-stage trials of
Johnson & Johnson’s
Covid-19 vaccine are giving experts increased confidence that the vaccine will work as they await results of a large Phase 3 trial expected in the coming weeks.
The trial data, published Wednesday by the New England Journal of Medicine, offered an expanded and updated account of a paper posted weeks ago on a so-called preprint server. The paper showed that 90% or more of participants developed neutralizing antibodies against the virus that causes Covid-19 within 29 days after injection with the Johnson & Johnson vaccine, and that the neutralizing antibodies remained 71 days after injection.
Shares of Johnson & Johnson were up 1.8% in premarket trading on Thursday.

New-york , United-states , Moncef-slaoui , Louise-chen , Josh-nathan-kazis , Jared-holz , Scott-eells-bloomberg , Johnson-covid , Pfizer , New-york-times , Cantor-fitzgerald , Drug-administration

Space Stocks Are Rocketing Higher. What's Behind Their Big Moves.

VMware,
Pat Gelsinger, effective Feb. 15.
Since Swan took over in 2019, Intel has divested from non-core assets while making acquisitions that
strengthened its core business. But as
Barron’s notes, “Swan doesn’t have semiconductors in his DNA and is known as more of a software and finance executive than a man with deep technical expertise.”
Gelsinger, on the other hand, is
a prominent technical expert in the chip industry. He’s a trained engineer who has written a microprocessor programming book, holds several patents, helped create Wi-Fi technology and spent three decades at Intel earlier in his career.
“After careful consideration, the board concluded that now is the right time to make this leadership change to draw on Pat’s technology and engineering expertise during this critical period of transformation at Intel,” Intel chairman Omar Ishrak said in a statement.

United-states , Georgia , Nebraska , Alaska , Singapore , White-house , District-of-columbia , China , Pennsylvania , Wuhan , Hubei , Ukraine

Covid-19 Infection Likely to Provide Immunity for at Least Five Months, Study Finds. What That Might Mean.

By
Lina Saigol
Order Reprints
Text size
The preliminary findings provided no evidence toward responses from Covid-19 vaccines, which the study will consider later this year.
Getty Images
People who have had Covid-19 are likely to be protected from reinfection for at least five months, a preliminary study of health care workers in the U.K. has found.
However, researchers warned those with immunity may still carry the virus in their nose and throat—risking transmitting it to others. The Public Health England (PHE) SIREN study, involving more than 20,000 health care workers, was published on Thursday and hasn’t yet been peer-reviewed.

Germany , German , Susan-hopkins , Simon-clarke , Julian-tang , Lawrence-young , Warwick-medical-school , University-of-leicester , University-of-oxford , Pfizer , Uk-national-health-service , University-of-reading

China's Coronavirus Outbreak Collides With Confusion Over Vaccine Efficacy

Order Reprints
Print Article
China is facing the worst resurgence of the coronavirus since it quashed nearly all of its cases months ago, adding pressure to the rollout of vaccines to its vast population.
Amid this pressure is recent news from Brazil that a Chinese-developed vaccine showed significantly lower efficacy rate in very mild cases compared to its global peers.
China...
Close
China’s Coronavirus Outbreak Collides With Confusion Over Vaccine Efficacy
China is facing the worst resurgence of the coronavirus since it quashed nearly all of its cases months ago, adding pressure to the rollout of vaccines to its vast population.

Sao-paulo , Sãpaulo , Brazil , Seoul , Soult-ukpyolsi , South-korea , Wang-bin , Liaoning , China , Hong-kong , Beijing , Indonesia

Want to Use ETFs to Play Biotech? Selectivity Is a Must.

Dreamstime
Biotech companies have been riding the wave of Covid-19 vaccine excitement for months now, as the pandemic reignited investors’ confidence in the value of their research, technology, and platforms.
Leaders in coronavirus vaccine development like
Moderna
(ticker: MRNA) and
Novavax
(NVAX) have seen their stocks surge wildly, but the rally isn’t limited to them. The biggest winners in 2020 also included firms with breakthroughs in other areas, such as
Twist Bioscience
(TWST), which developed a DNA synthesis platform that made Covid testing possible, and
Investing in biotech isn’t easy, however. It’s a risky space where companies often have no income-generating products, and the drugs in development have no guarantee of government approval. Investors are often attracted by biotech stocks’ potential for outsize gains, but these companies can also bring sudden, steep declines if their high-stake efforts fail in clinical trials.

Elizabeth-kashner , Evie-liu , Gilead-sciences , Nasdaq , Twist-bioscience , Seres-therapeutics , Shares-nasdaq-biotechnology , Industry-classification , Global-industry-classification-standard , Fate-therapeutics , Biotechnology , Pharmaceuticals